These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28404093)

  • 1. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
    Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T
    Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
    Ambrosini M; Rousseau B; Manca P; Artz O; Marabelle A; André T; Maddalena G; Mazzoli G; Intini R; Cohen R; Cercek A; Segal NH; Saltz L; Varghese AM; Yaeger R; Nusrat M; Goldberg Z; Ku GY; El Dika I; Margalit O; Grinshpun A; Murtaza Kasi P; Schilsky R; Lutfi A; Shacham-Shmueli E; Khan Afghan M; Weiss L; Westphalen CB; Conca V; Decker B; Randon G; Elez E; Fakih M; Schrock AB; Cremolini C; Jayachandran P; Overman MJ; Lonardi S; Pietrantonio F
    Ann Oncol; 2024 Jul; 35(7):643-655. PubMed ID: 38777726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE-hypermutated colorectal cancers.
    Favre L; Cohen J; Calderaro J; Pécriaux A; Nguyen CT; Bourgoin R; Larnaudie L; Dupuy A; Ollier M; Lechapt E; Sloma I; Tournigand C; Rousseau B; Pujals A
    Mol Oncol; 2022 Sep; 16(17):3055-3065. PubMed ID: 35624529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Treatment for
    Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M
    Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562
    [No Abstract]   [Full Text] [Related]  

  • 7. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
    Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
    Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
    Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
    Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
    van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
    Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
    Hwang HS; Kim D; Choi J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of POLE proofreading mutations in endometrial cancer.
    Church DN; Stelloo E; Nout RA; Valtcheva N; Depreeuw J; ter Haar N; Noske A; Amant F; Tomlinson IP; Wild PJ; Lambrechts D; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Creutzberg CL; Bosse T
    J Natl Cancer Inst; 2015 Jan; 107(1):402. PubMed ID: 25505230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.
    Kothari N; Teer JK; Abbott AM; Srikumar T; Zhang Y; Yoder SJ; Brohl AS; Kim RD; Reed DR; Shibata D
    Cancer; 2016 Sep; 122(18):2828-35. PubMed ID: 27244218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
    Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
    Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.
    Vande Perre P; Siegfried A; Corsini C; Bonnet D; Toulas C; Hamzaoui N; Selves J; Chipoulet E; Hoffmann JS; Uro-Coste E; Guimbaud R
    Fam Cancer; 2019 Apr; 18(2):173-178. PubMed ID: 30368636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.